Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy

Journal of Medical Virology

Volumn 82, Issue 10, 2010, Pages 1640-1646

  François, Catherine ^a   Descamps, Véronique ^a   Brochot, Etienne ^a   Bernard, Isabelle ^a   Canva, Valérie ^b   Mathurin, Philippe ^b,c   Castelain, Sandrine ^a   Duverlie, Gilles ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

Author keywords

HCV; Hepatitis C; IFN; Interferon; Pharmacokinetics

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERFERONS; MALE; POLYETHYLENE GLYCOLS; RIBAVIRIN; SERUM; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 77956588887     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21837     Document Type: Article

References (30)

1. Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS. 2001. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 33:419-423.
2. Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, Filice G. 2004. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: A randomized, controlled study. Antivir Ther 9:491-497.
3. Bruno R, Sacchi P, Scagnolari C, Torriani F, Maiocchi L, Patruno S, Bellomi F, Filice G, Antonelli G. 2007. Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naive patients with chronic hepatitis C: A randomized, controlled study. Aliment Pharmacol Ther 26:369-376.
4. Castelain S, Descamps V, Thibault V, Francois C, Bonte D, Morel V, Izopet J, Capron D, Zawadzki P, Duverlie G. 2004. TaqMan amplification system with an internal positive control for HCV RNA quantitation. J Clin Virol 31:227-234.
5. Deltenre P, Canva V, El Nady M, Francois C, Castelain S, Dharancy S, Louvet A, Bocket L, Lazrek M, Hollebecque A, Wartel F, Henrion J, Duverlie G, Mathurin P. 2009. A 2-log drop in viral load at 1 month is the best predictor of sustained response in HCV patients with normal ALT: A kinetic prospective study. J Viral Hepat 16:500-505.
6. Dhumeaux D, Marcellin P, Lerebours E. 2003. Treatment of hepatitis C. The 2002 French consensus. Gut 52:1784-1787.
7. Formann E, Jessner W, Bennett L, Ferenci P. 2003. Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat 10:271-276.
8. Francois C, Bernard I, Castelain S, Charleston B, Fray MD, Capiod JC, Duverlie G. 2005. Quantification of different human alpha interferon subtypes and pegylated interferon activities by measuring MxA promoter activation. Antimicrob Agents Chemother 49:3770-3775.
9. Francois C, Castelain S, Duverlie G, Capron D, Nguyen-Khac E. 2009. Optimizing the treatment of chronic viral hepatitis C. Expert Rev Gastroenterol Hepatol 3:607-613.
10. Fray MD, Mann GE, Charleston B. 2001. Validation of an Mx/CAT reporter gene assay for the quantification of bovine type-I interferon. J Immunol Methods 249:235-244.
11. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
12. Galeras JA GM, Marquez C, Cirera I, Coll S, Sola R. 2006. Predictive value and predictive factors of the rapid virological response in chronic hepatitis C treatment. EASL Abstract. J Hepatol 44:S212-S213.
13. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S. 2000a. Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 68:556-567.
14. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Clement RP. 2000b. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 32:647-653.
15. Grace M, Youngster S, Gitlin G, Sydor W, Xie L, Westreich L, Jacobs S, Brassard D, Bausch J, Bordens R. 2001. Structural and biologic characterization of pegylated recombinant IFN-alpha2b. J Interferon Cytokine Res 21:1103-1115.
16. Harris JM, Martin NE, Modi M. 2001. Pegylation: A novel process for modifying pharmacokinetics. Clin Pharmacokinet 40:539-551.
17. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. 2006. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43:954-960.
18. Jessner W, Stauber R, Hackl F, Datz C, Watkins-Riedel T, Hofer H, Gangl A, Kessler H, Ferenci P. 2003. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. J Viral Hepat 10:37-42.
19. Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, Vinelli F, Scotto G, Montalto G, Romano M, Cristofaro G, Mottola L, Spirito F, Andriulli A. 2008. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology 47:43-50.
20. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958-965. (Pubitemid 32913521)
21. Martinot-Peignoux M, Maylin S, Moucari R, Ripault MP, Boyer N, Cardoso AC, Giuily N, Castelnau C, Pouteau M, Stern C, Auperin A, Bedossa P, Asselah T, Marcellin P. 2009. Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. Antivir Ther 14:501-511.
22. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339:1485-1492.
23. Nyberg L, Albrecht J, Glue P, Gianelli G, Zambas D, Elliot M, Conrad A, McHutchison J. 1999. Changes in serum hepatitis C virus RNA in interferon nonresponders retreated with interferon plus ribavirin: A preliminary report. J Clin Gastroenterol 28:313-316.
24. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352:1426-1432.
25. Rosen HR, Ribeiro RR, Weinberger L, Wolf S, Chung M, Gretch DR, Perelson AS. 2002. Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. J Hepatol 37:124-130.
26. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. 2006. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 43:1303-1310.
27. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, Heim MH. 2008. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 105:7034-7039.
28. Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF. 2002. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 54:547-570.
29. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. 2007. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 22:832-836.
30. Zeuzem S, Welsch C, Herrmann E. 2003. Pharmacokinetics of peginterferons. Semin Liver Dis 23:23-28.